Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein-Reference-Cited by-同舟云学术

Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein

Published:2014-05-08 Issue:4 Volume:20 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

McCue J.¹,Osborne D.¹,Dumont J.¹,Peters R.¹,Mei B.¹,Pierce G. F.¹,Kobayashi K.¹,Euwart D.¹

Affiliation:

1. Biogen Idec Cambridge MA USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12451

Reference37 articles.

1. Haemophilias A and B

2. Ham-Wasserman Lecture

3. Medical and Scientific Advisory Council (MASAC).Recommendation Concerning Prophylaxis. Available athttp://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed September 3 2013.

4. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

5. The Hemophilias — From Royal Genes to Gene Therapy

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18

2. Advances and challenges in the purification of recombinant coagulation factors: A review;Journal of Chromatography A;2024-02

3. Eftrenonacog Alfa: A Review in Haemophilia B;Drugs;2023-04-21

4. Generation of Human 293-F Suspension NGFR Knockout Cells Using CRISPR/Cas9 Coupled to Fluorescent Protein Expression;Methods in Molecular Biology;2023

5. Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies;Frontiers in Bioengineering and Biotechnology;2021-08-20